$REMEGEN(09995.HK), $TRANSTHERA-B(02617.HK), and $ALI HEALTH(00241.HK) all rose slightly 😀
The bullish sentiment in Hong Kong's pharmaceutical sector continues. Expectations for ADC licensing overseas, the potential for volume sales of innovative drugs, and the monetization of traffic in internet healthcare have all attracted early capital inflows across the value chain. As the innovative drug theme has progressed to this point, the rotation among individual stocks is more worth watching than the overall sector beta.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
